Actos Lawsuit News: Appellate Court Reinstates $6.5 Million Jury Award

Actos Lawsuit News: Appellate Court Reinstates $6.5 Million Jury Award

In a significant development in the Actos litigation, the California State Appeals Court for the Second District last week reinstated a cancer patient and spouse’s $6.5 million jury award against the makers of Actos, a diabetes medication. The appellate court’s decision reaffirms the importance and role of the jury in deciding claims.

[Read more…]

Actos Bladder Cancer Lawsuits Settlement Summary

Actos Bladder Cancer Lawsuits Settlement Summary - Courtroom image

On April 28, 2015, U.S. District Court Judge Rebecca F. Doherty, the judge overseeing the Actos injury cases in federal court nationwide, issued an order recognizing that Takeda, the manufacturer of Actos, has agreed to settle all bladder cancer claims brought against the company by Actos users who satisfy the following three conditions:

[Read more…]

Actos Bladder Cancer Lawsuit Video

Actos drug imagePatients who developed bladder cancer after being prescribed the diabetes medication Actos (brand name for the drug pioglitazone) have filed lawsuits against the manufacturer of Actos charging that it did not adequately warn of its cancer risks. Drug makers have a duty to warn of all serious side effects from their medications. These videos discuss the link between Actos and bladder cancer and summarize the charged made in the Actos bladder cancer lawsuits.

[Read more…]

Federal Jury Awards Punitive Damages In Actos Bladder Cancer Trial

Federal Jury Awards Punitive Damages in Actos Trial

A federal jury in Louisiana yesterday ordered Takeda Pharmaceutical Company and Eli Lilly & Company to pay $1,475,000 in compensatory damages, finding that they failed to adequately warn about bladder-cancer risks of their diabetes medicine Actos. Jurors also found that Takeda and Lilly executives acted with wanton and reckless disregard for patient safety in their handling of the drug, and awarded a total of $9 billion in punitive damages against both companies.

[Read more…]